{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T07:57:36Z","timestamp":1785571056876,"version":"3.56.0"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"DOI":"10.1007\/s12026-026-09812-z","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T05:46:58Z","timestamp":1785563218000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Past achievements and future perspectives of personalized vaccines and the role of dendritic cells"],"prefix":"10.1007","volume":"74","author":[{"given":"Mona","family":"Sadat Larijani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahita","family":"Bavand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladan","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitis","family":"Ramezani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"issue":"12","key":"9812_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13121231","volume":"13","author":"L Lu","year":"2025","unstructured":"Lu L, Lu X, Luo W. Personalized cancer vaccines: current advances and emerging horizons. Vaccines (Basel). 2025;13(12):1231.","journal-title":"Vaccines (Basel)"},{"key":"9812_CR2","doi-asserted-by":"publisher","unstructured":"Montin D, Santilli V, Beni A, Costagliola G, Martire B, Mastrototaro MF, et al. Towards personalized vaccines. Front Immunol. 2024;15:1436108. https:\/\/doi.org\/10.3389\/fimmu.2024.1436108","DOI":"10.3389\/fimmu.2024.1436108"},{"key":"9812_CR3","volume":"46","author":"NK Alaqeel","year":"2026","unstructured":"Alaqeel NK. Advances in personalized cancer vaccine to nanotechnology innovations. Cancer Treat Res Commun. 2026;46:101060.","journal-title":"Cancer Treat Res Commun"},{"key":"9812_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.70006","author":"L Iamukova","year":"2025","unstructured":"Iamukova L, Alferova E. Personalized cancer vaccines in the clinical trial pipeline. Asia-Pac J Clin Oncol. 2025. https:\/\/doi.org\/10.1111\/ajco.70006.","journal-title":"Asia-Pac J Clin Oncol"},{"key":"9812_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102383","author":"H Fritah","year":"2022","unstructured":"Fritah H, Rovelli R, Chiang CL, Kandalaft LE. The current clinical landscape of personalized cancer vaccines. Cancer Treat Rev. 2022;106:102383. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102383.","journal-title":"Cancer Treat Rev"},{"issue":"7738","key":"9812_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565(7738):234\u20139.","journal-title":"Nature"},{"issue":"7662","key":"9812_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217\u201321.","journal-title":"Nature"},{"issue":"3","key":"9812_CR8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nri.2017.131","volume":"18","author":"Z Hu","year":"2018","unstructured":"Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168\u201382.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"9812_CR9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/PPO.0b013e318233e5b2","volume":"17","author":"CL Slingluff Jr","year":"2011","unstructured":"Slingluff CL Jr. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J (Sudbury Mass). 2011;17(5):343\u201350.","journal-title":"Cancer J (Sudbury Mass)"},{"key":"9812_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110721","volume":"123","author":"F Zahedipour","year":"2023","unstructured":"Zahedipour F, Jamialahmadi K, Zamani P, Reza Jaafari M. Improving the efficacy of peptide vaccines in cancer immunotherapy. Int Immunopharmacol. 2023;123:110721.","journal-title":"Int Immunopharmacol"},{"key":"9812_CR11","doi-asserted-by":"publisher","unstructured":"Laila UE, An W, Xu ZX. Emerging prospects of mRNA cancer vaccines: mechanisms, formulations, and challenges in cancer immunotherapy. Front Immunol. 2024;15:1448489. https:\/\/doi.org\/10.3389\/fimmu.2024.1448489","DOI":"10.3389\/fimmu.2024.1448489"},{"issue":"1","key":"9812_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12951-025-03800-5","volume":"24","author":"Y Quan","year":"2025","unstructured":"Quan Y, Yang H, Li W, Li L. mRNA vaccines: immunogenicity and quality characteristics. J Nanobiotechnol. 2025;24(1):6.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"9812_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02542-y","volume":"16","author":"J-y Li","year":"2025","unstructured":"Li J-y, Jiang R-y, Wang J, Wang X-j. Advances in mRNA vaccine therapy for breast cancer research. Discov Oncol. 2025;16(1):673.","journal-title":"Discov Oncol"},{"issue":"7662","key":"9812_CR14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin U, Derhovanessian E, Miller M, Kloke B-P, Simon P, L\u00f6wer M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222\u20136.","journal-title":"Nature"},{"issue":"10432","key":"9812_CR15","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S0140-6736(23)02444-3","volume":"403","author":"H Parhiz","year":"2024","unstructured":"Parhiz H, Atochina-Vasserman EN, Weissman D. mRNA-based therapeutics: looking beyond COVID-19 vaccines. Lancet. 2024;403(10432):1192\u2013204.","journal-title":"Lancet"},{"key":"9812_CR16","first-page":"1","volume":"33","author":"B Sanchari","year":"2026","unstructured":"Sanchari B, Nilufa E, Atanu P, Aditi N, Debjeet S. mRNA-Based Cancer Vaccines: A Review of the Current Scenario and Future Prospects. Protein Pept Lett. 2026;33:1\u201315.","journal-title":"Protein Pept Lett"},{"issue":"3","key":"9812_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","volume":"24","author":"PD Katsikis","year":"2024","unstructured":"Katsikis PD, Ishii KJ, Schliehe C. Challenges in developing personalized neoantigen cancer vaccines. Nat Rev Immunol. 2024;24(3):213\u201327.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"9812_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.29252\/JoMMID.7.4.89","volume":"7","author":"M Sadat Larijani","year":"2019","unstructured":"Sadat Larijani M, Sadat SM, Bolhassani A, Ramezani A. A Shot at Dendritic Cell-Based Vaccine Strategy against HIV-1. JoMMID. 2019;7(4):89.","journal-title":"JoMMID"},{"key":"9812_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cells12172147","author":"KW Lee","year":"2023","unstructured":"Lee KW, Yam JWP, Mao X. Dendritic cell vaccines: a shift from conventional approach to new generations. Cells. 2023;12(17):2147. https:\/\/doi.org\/10.3390\/cells12172147.","journal-title":"Cells"},{"issue":"5","key":"9812_CR20","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/14653240902960411","volume":"11","author":"A Van Driessche","year":"2009","unstructured":"Van Driessche A, Van de Velde AL, Nijs G, Braeckman T, Stein B, De Vries JM, et al. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy. 2009;11(5):653\u201368.","journal-title":"Cytotherapy"},{"issue":"6382","key":"9812_CR21","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.aar7112","volume":"359","author":"U Sahin","year":"2018","unstructured":"Sahin U, T\u00fcreci \u00d6. Personalized vaccines for cancer immunotherapy. Science. 2018;359(6382):1355\u201360.","journal-title":"Science"},{"issue":"5","key":"9812_CR22","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1039\/D3MH00092C","volume":"10","author":"Z Yu","year":"2023","unstructured":"Yu Z, Wang D, Qi Y, Liu J, Zhou T, Rao W, et al. Autologous-cancer-cryoablation-mediated nanovaccine augments systematic immunotherapy. Mater Horiz. 2023;10(5):1661\u201377.","journal-title":"Mater Horiz"},{"issue":"14","key":"9812_CR23","doi-asserted-by":"publisher","first-page":"13278","DOI":"10.1021\/acsnano.3c00941","volume":"17","author":"D Wang","year":"2023","unstructured":"Wang D, Yu Z, Qi Y, Hu K, Zhou T, Liu J, et al. Liquid metal nanoplatform based autologous cancer vaccines. ACS Nano. 2023;17(14):13278\u201395.","journal-title":"ACS Nano"},{"issue":"5","key":"9812_CR24","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/nrd2224","volume":"6","author":"AW Purcell","year":"2007","unstructured":"Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov. 2007;6(5):404\u201314.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"9812_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines \u2014 a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261\u201379.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"9812_CR26","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.4161\/rna.22269","volume":"9","author":"T Schlake","year":"2012","unstructured":"Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biol. 2012;9(11):1319\u201330.","journal-title":"RNA Biol"},{"issue":"1","key":"9812_CR27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","volume":"39","author":"K Palucka","year":"2013","unstructured":"Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013;39(1):38\u201348.","journal-title":"Immunity"},{"issue":"11","key":"9812_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1638212","volume":"8","author":"J Sprooten","year":"2019","unstructured":"Sprooten J, Ceusters J, Coosemans A, Agostinis P, De Vleeschouwer S, Zitvogel L, et al. Trial watch: dendritic cell vaccination for cancer immunotherapy. Oncoimmunology. 2019;8(11):1638212.","journal-title":"Oncoimmunology"},{"issue":"6230","key":"9812_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62\u20138.","journal-title":"Science"},{"issue":"6382","key":"9812_CR30","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Sci (New York NY). 2018;359(6382):1361\u20135.","journal-title":"Sci (New York NY)"},{"issue":"7","key":"9812_CR31","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917\u201324.","journal-title":"J Clin Oncol"},{"issue":"8","key":"9812_CR32","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1158\/1078-0432.CCR-15-1399","volume":"22","author":"KF Bol","year":"2016","unstructured":"Bol KF, Schreibelt G, Gerritsen WR, de Vries IJ, Figdor CG. Dendritic Cell-Based Immunotherapy: State of the Art and Beyond. Clin cancer research: official J Am Association Cancer Res. 2016;22(8):1897\u2013906.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"key":"9812_CR33","first-page":"803","volume-title":"Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells","author":"BM Carreno","year":"2015","unstructured":"Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Volume 348. New York, NY: Science; 2015. pp. 803\u20138. 6236."},{"issue":"7528","key":"9812_CR34","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371.","journal-title":"Nature"},{"issue":"7528","key":"9812_CR35","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563\u20137.","journal-title":"Nature"},{"issue":"25","key":"9812_CR36","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin oncology: official J Am Soc Clin Oncol. 2015;33(25):2780\u20138.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"9812_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001621","author":"J Malvehy","year":"2021","unstructured":"Malvehy J, Samoylenko I, Schadendorf D, Gutzmer R, Grob JJ, Sacco JJ, et al. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma. J Immunother Cancer. 2021;9(3):e001621. https:\/\/doi.org\/10.1136\/jitc-2020-001621.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"9812_CR38","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.immuni.2016.08.015","volume":"45","author":"M Guilliams","year":"2016","unstructured":"Guilliams M, Dutertre C-A, Scott CL, McGovern N, Sichien D, Chakarov S, et al. Unsupervised high-dimensional analysis aligns dendritic cells across tissues and species. Immunity. 2016;45(3):669\u201384.","journal-title":"Immunity"},{"issue":"2","key":"9812_CR39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41577-018-0088-1","volume":"19","author":"SC Eisenbarth","year":"2019","unstructured":"Eisenbarth SC. Dendritic cell subsets in T cell programming: location dictates function. Nat Rev Immunol. 2019;19(2):89\u2013103.","journal-title":"Nat Rev Immunol"},{"issue":"5904","key":"9812_CR40","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.1164206","volume":"322","author":"K Hildner","year":"2008","unstructured":"Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Sci (New York NY). 2008;322(5904):1097\u2013100.","journal-title":"Sci (New York NY)"},{"issue":"5","key":"9812_CR41","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger S, Dai D, Horton B, Gajewski TF. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 2017;31(5):711-23.e4.","journal-title":"Cancer Cell"},{"issue":"5195","key":"9812_CR42","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1126\/science.7809629","volume":"267","author":"M Kovacsovics-Bankowski","year":"1995","unstructured":"Kovacsovics-Bankowski M, Rock KL. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science. 1995;267(5195):243\u20136.","journal-title":"Science"},{"issue":"4","key":"9812_CR43","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.immuni.2006.08.017","volume":"25","author":"AL Ackerman","year":"2006","unstructured":"Ackerman AL, Giodini A, Cresswell P. A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells. Immunity. 2006;25(4):607\u201317.","journal-title":"Immunity"},{"issue":"5","key":"9812_CR44","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/ni.1601","volume":"9","author":"S Burgdorf","year":"2008","unstructured":"Burgdorf S, Sch\u00f6lz C, Kautz A, Tamp\u00e9 R, Kurts C. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol. 2008;9(5):558\u201366.","journal-title":"Nat Immunol"},{"issue":"5","key":"9812_CR45","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.immuni.2013.04.011","volume":"38","author":"A Schlitzer","year":"2013","unstructured":"Schlitzer A, McGovern N, Teo P, Zelante T, Atarashi K, Low D, et al. IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Immunity. 2013;38(5):970\u201383.","journal-title":"Immunity"},{"issue":"5421","key":"9812_CR46","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1126\/science.284.5421.1835","volume":"284","author":"FP Siegal","year":"1999","unstructured":"Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, et al. The nature of the principal type 1 interferon-producing cells in human blood. Sci (New York NY). 1999;284(5421):1835\u20137.","journal-title":"Sci (New York NY)"},{"issue":"2","key":"9812_CR47","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.193.2.233","volume":"193","author":"MV Dhodapkar","year":"2001","unstructured":"Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 2001;193(2):233\u20138.","journal-title":"J Exp Med"},{"issue":"1","key":"9812_CR48","first-page":"12","volume":"63","author":"IJ De Vries","year":"2003","unstructured":"De Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, Van Muijen GN, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 2003;63(1):12\u20137.","journal-title":"Cancer Res"},{"issue":"7","key":"9812_CR49","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1084\/jem.20050732","volume":"202","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8\u2009+\u2009T cells. J Exp Med. 2005;202(7):907\u201312.","journal-title":"J Exp Med"},{"issue":"5","key":"9812_CR50","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411\u201322.","journal-title":"N Engl J Med"},{"issue":"3","key":"9812_CR51","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nm0398-328","volume":"4","author":"FO Nestle","year":"1998","unstructured":"Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4(3):328\u201332.","journal-title":"Nat Med"},{"issue":"6","key":"9812_CR52","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.4049\/jimmunol.174.6.3808","volume":"174","author":"Y He","year":"2005","unstructured":"He Y, Zhang J, Mi Z, Robbins P, Falo LD. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol. 2005;174(6):3808\u201317.","journal-title":"J Immunol"},{"issue":"6","key":"9812_CR53","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1084\/jem.194.6.769","volume":"194","author":"D Hawiger","year":"2001","unstructured":"Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 2001;194(6):769\u201379.","journal-title":"J Exp Med"},{"key":"9812_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.128059","volume":"71","author":"F Nowzari","year":"2015","unstructured":"Nowzari F, Nowzari F, Kian M, Zahedi M, Samimi K, Karimzadeh A, et al. Evolution and trends in non-viral mRNA cancer vaccines: a scoping review from 2015 to 2025. Vaccine. 2015;71:128059.","journal-title":"Vaccine"},{"issue":"1","key":"9812_CR55","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood.V98.1.49","volume":"98","author":"VFI Van Tendeloo","year":"2001","unstructured":"Van Tendeloo VFI, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C, et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood. 2001;98(1):49\u201356.","journal-title":"Blood"},{"issue":"7963","key":"9812_CR56","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144\u201350.","journal-title":"Nature"},{"issue":"1","key":"9812_CR57","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41541-023-00733-8","volume":"8","author":"K Qiu","year":"2023","unstructured":"Qiu K, Duan X, Mao M, Song Y, Rao Y, Cheng D, et al. mRNA-LNP vaccination-based immunotherapy augments CD8\u2009+\u2009T cell responses against HPV-positive oropharyngeal cancer. npj Vaccines. 2023;8(1):144.","journal-title":"npj Vaccines"},{"issue":"6","key":"9812_CR58","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/gt.2011.1","volume":"18","author":"JC Steele","year":"2011","unstructured":"Steele JC, Rao A, Marsden JR, Armstrong CJ, Berhane S, Billingham LJ, et al. Phase I\/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma. Gene Ther. 2011;18(6):584\u201393.","journal-title":"Gene Ther"},{"key":"9812_CR59","doi-asserted-by":"publisher","DOI":"10.1111\/imm.70033","author":"J Shpigelman","year":"2025","unstructured":"Shpigelman J, Rao K. Dendritic cell-derived extracellular vesicles as therapeutic cancer vaccines: mechanisms and optimization strategies. Immunology. 2025. https:\/\/doi.org\/10.1111\/imm.70033.","journal-title":"Immunology"},{"issue":"1","key":"9812_CR60","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1038\/s41467-023-39759-w","volume":"14","author":"X Liu","year":"2023","unstructured":"Liu X, Zhuang Y, Huang W, Wu Z, Chen Y, Shan Q, et al. Interventional hydrogel microsphere vaccine as an immune amplifier for activated antitumour immunity after ablation therapy. Nat Commun. 2023;14(1):4106.","journal-title":"Nat Commun"},{"issue":"17","key":"9812_CR61","doi-asserted-by":"publisher","first-page":"5934","DOI":"10.1158\/0008-5472.CAN-04-1261","volume":"64","author":"RB Mailliard","year":"2004","unstructured":"Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, et al. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004;64(17):5934\u20137.","journal-title":"Cancer Res"},{"issue":"7549","key":"9812_CR62","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nature14426","volume":"520","author":"S Kreiter","year":"2015","unstructured":"Kreiter S, Vormehr M, van de Roemer N, Diken M, L\u00f6wer M, Diekmann J, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015;520(7549):692\u20136.","journal-title":"Nature"},{"issue":"6","key":"9812_CR63","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21(6):360\u201378.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"9812_CR64","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jcyt.2014.03.005","volume":"16","author":"P Hourd","year":"2014","unstructured":"Hourd P, Ginty P, Chandra A, Williams DJ. Manufacturing models permitting roll out\/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability. Cytotherapy. 2014;16(8):1033\u201347.","journal-title":"Cytotherapy"},{"issue":"8","key":"9812_CR65","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.biotechadv.2013.08.009","volume":"31","author":"S Abbasalizadeh","year":"2013","unstructured":"Abbasalizadeh S, Baharvand H. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies. Biotechnol Adv. 2013;31(8):1600\u201323.","journal-title":"Biotechnol Adv"},{"issue":"3","key":"9812_CR66","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","volume":"183","author":"DK Wells","year":"2020","unstructured":"Wells DK, van Buuren MM, Dang KK, Hubbard-Lucey VM, Sheehan KCF, Campbell KM, et al. Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell. 2020;183(3):818-34.e13.","journal-title":"Cell"},{"issue":"7681","key":"9812_CR67","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nature24473","volume":"551","author":"M \u0141uksza","year":"2017","unstructured":"\u0141uksza M, Riaz N, Makarov V, Balachandran VP, Hellmann MD, Solovyov A, et al. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature. 2017;551(7681):517\u201320.","journal-title":"Nature"},{"issue":"4","key":"9812_CR68","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613\u201328.","journal-title":"Cell"},{"issue":"7749","key":"9812_CR69","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","volume":"567","author":"R Rosenthal","year":"2019","unstructured":"Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, et al. Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019;567(7749):479\u201385.","journal-title":"Nature"},{"key":"9812_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16050981","author":"L Hato","year":"2024","unstructured":"Hato L, Vizcay A, Eguren I, P\u00e9rez-Gracia JL, Rodr\u00edguez J, G\u00e1llego P\u00e9rez-Larraya J, et al. Dendritic cells in cancer immunology and immunotherapy. Cancers (Basel). 2024;16(5):981. https:\/\/doi.org\/10.3390\/cancers16050981.","journal-title":"Cancers"},{"issue":"5","key":"9812_CR71","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","volume":"26","author":"ML Broz","year":"2014","unstructured":"Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014;26(5):638\u201352.","journal-title":"Cancer Cell"},{"issue":"3","key":"9812_CR72","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.cell.2019.02.005","volume":"177","author":"M Binnewies","year":"2019","unstructured":"Binnewies M, Mujal AM, Pollack JL, Combes AJ, Hardison EA, Barry KC, et al. Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4(+) T Cell Immunity. Cell. 2019;177(3):556\u2013e7116.","journal-title":"Cell"},{"issue":"5","key":"9812_CR73","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541\u201350.","journal-title":"Nat Med"},{"issue":"6230","key":"9812_CR74","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Sci (New York NY). 2015;348(6230):74\u201380.","journal-title":"Sci (New York NY)"},{"issue":"7607","key":"9812_CR75","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","volume":"534","author":"LM Kranz","year":"2016","unstructured":"Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534(7607):396\u2013401.","journal-title":"Nature"},{"issue":"12","key":"9812_CR76","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1084\/jem.20021598","volume":"196","author":"L Bonifaz","year":"2002","unstructured":"Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med. 2002;196(12):1627\u201338.","journal-title":"J Exp Med"},{"issue":"6","key":"9812_CR77","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1084\/jem.20032220","volume":"199","author":"LC Bonifaz","year":"2004","unstructured":"Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med. 2004;199(6):815\u201324.","journal-title":"J Exp Med"},{"issue":"1","key":"9812_CR78","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.cels.2020.06.010","volume":"11","author":"TJ O\u2019Donnell","year":"2020","unstructured":"O'Donnell TJ, Rubinsteyn A, Laserson U. MHCflurry 2.0: improved pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing. Cell Syst. 2020;11(1):42\u20138.e7. https:\/\/doi.org\/10.1016\/j.cels.2020.06.010","journal-title":"Cell Syst"},{"issue":"8","key":"9812_CR79","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s42256-023-00694-6","volume":"5","author":"BA Albert","year":"2023","unstructured":"Albert BA, Yang Y, Shao XM, Singh D, Smith KN, Anagnostou V, et al. Deep neural networks predict class I major histocompatibility complex epitope presentation and transfer learn neoepitope immunogenicity. Nat Mach Intell. 2023;5(8):861\u201372.","journal-title":"Nat Mach Intell"},{"key":"9812_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13082012","author":"X Xun","year":"2025","unstructured":"Xun X, Hao J, Cheng Q, Gao P. Induced pluripotent stem cell-based cancer immunotherapy: strategies and perspectives. Biomedicines. 2025. https:\/\/doi.org\/10.3390\/biomedicines13082012.","journal-title":"Biomedicines"},{"issue":"8","key":"9812_CR81","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38(8):947\u201353.","journal-title":"Nat Biotechnol"},{"issue":"9","key":"9812_CR82","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1182\/blood-2002-07-2254","volume":"101","author":"S Senju","year":"2003","unstructured":"Senju S, Hirata S, Matsuyoshi H, Masuda M, Uemura Y, Araki K, et al. Generation and genetic modification of dendritic cells derived from mouse embryonic stem cells. Blood. 2003;101(9):3501\u20138.","journal-title":"Blood"},{"issue":"25","key":"9812_CR83","doi-asserted-by":"publisher","first-page":"16168","DOI":"10.1073\/pnas.242600099","volume":"99","author":"C Yee","year":"2002","unstructured":"Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, et al. Adoptive T cell therapy using antigen-specific CD8\u2009+\u2009T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA. 2002;99(25):16168\u201373.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"9812_CR84","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","volume":"27","author":"Z Hu","year":"2021","unstructured":"Hu Z, Leet DE, Alles\u00f8e RL, Oliveira G, Li S, Luoma AM, et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med. 2021;27(3):515\u201325.","journal-title":"Nat Med"},{"issue":"10427","key":"9812_CR85","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet (London England). 2024;403(10427):632\u201344.","journal-title":"Lancet (London England)"},{"issue":"20","key":"9812_CR86","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020;383(20):1920\u201331.","journal-title":"N Engl J Med"},{"issue":"27","key":"9812_CR87","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603\u201315.","journal-title":"N Engl J Med"},{"issue":"5","key":"9812_CR88","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403\u201316.","journal-title":"N Engl J Med"},{"key":"9812_CR89","unstructured":"Pfizer. and BioNTech Reach an Agreement to Supply the EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-2 [Internet]. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-reach-agreement-supply-eu-200-million?utm_source=chatgpt.com"},{"issue":"11","key":"9812_CR90","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","volume":"20","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021;20(11):817\u201338.","journal-title":"Nat Rev Drug Discov"},{"issue":"6583","key":"9812_CR91","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1126\/science.abl5447","volume":"375","author":"FJ Lowery","year":"2022","unstructured":"Lowery FJ, Krishna S, Yossef R, Parikh NB, Chatani PD, Zacharakis N, et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science (New York, NY). 2022;375(6583):877\u201384.","journal-title":"Science (New York, NY)"},{"key":"9812_CR92","doi-asserted-by":"publisher","first-page":"e068632","DOI":"10.1136\/bmj-2021-068632","volume":"376","author":"A Lee","year":"2022","unstructured":"Lee A, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376:e068632.","journal-title":"BMJ"},{"issue":"1","key":"9812_CR93","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nm1520","volume":"13","author":"P Kiepiela","year":"2007","unstructured":"Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med. 2007;13(1):46\u201353.","journal-title":"Nat Med"},{"issue":"1\u20132","key":"9812_CR94","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1023\/A:1008128212380","volume":"21","author":"U Protzer","year":"2000","unstructured":"Protzer U, Schaller H. Immune escape by hepatitis B viruses. Virus Genes. 2000;21(1\u20132):27\u201337.","journal-title":"Virus Genes"},{"issue":"7898","key":"9812_CR95","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602(7898):657\u201363.","journal-title":"Nature"},{"issue":"6","key":"9812_CR96","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.cell.2022.01.018","volume":"185","author":"K R\u00f6ltgen","year":"2022","unstructured":"R\u00f6ltgen K, Nielsen SCA, Silva O, Younes SF, Zaslavsky M, Costales C, et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell. 2022;185(6):1025-40.e14.","journal-title":"Cell"},{"issue":"13","key":"9812_CR97","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1056\/NEJMc2111462","volume":"385","author":"VG Hall","year":"2021","unstructured":"Hall VG, Ferreira VH, Ku T, Ierullo M, Majchrzak-Kita B, Chaparro C, et al. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. N Engl J Med. 2021;385(13):1244\u20136.","journal-title":"N Engl J Med"},{"issue":"7","key":"9812_CR98","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1056\/NEJMc2108861","volume":"385","author":"N Kamar","year":"2021","unstructured":"Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385(7):661\u20132.","journal-title":"N Engl J Med"},{"issue":"9","key":"9812_CR99","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data. J Immunol (Baltimore Md: 1950). 2017;199(9):3360\u20138.","journal-title":"J Immunol (Baltimore Md: 1950)"},{"issue":"2","key":"9812_CR100","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s42256-024-00971-y","volume":"7","author":"J Wohlwend","year":"2025","unstructured":"Wohlwend J, Nathan A, Shalon N, Crain CR, Tano-Menka R, Goldberg B, et al. Deep learning enhances the prediction of HLA class I-presented CD8(+) T cell epitopes in foreign pathogens. Nat Mach Intell. 2025;7(2):232\u201343.","journal-title":"Nat Mach Intell"},{"key":"9812_CR101","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btad187","author":"Y Zeng","year":"2023","unstructured":"Zeng Y, Wei Z, Yuan Q, Chen S, Yu W, Lu Y, et al. Identifying B-cell epitopes using AlphaFold2 predicted structures and pretrained language model. Bioinformatics. 2023;39(4):btad187. https:\/\/doi.org\/10.1093\/bioinformatics\/btad187.","journal-title":"Bioinformatics"},{"issue":"6","key":"9812_CR102","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00251-010-0441-4","volume":"62","author":"T Stranzl","year":"2010","unstructured":"Stranzl T, Larsen MV, Lundegaard C, Nielsen M. NetCTLpan: pan-specific MHC class I pathway epitope predictions. Immunogenetics. 2010;62(6):357\u201368.","journal-title":"Immunogenetics"},{"issue":"2","key":"9812_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100194","volume":"2","author":"J Schmidt","year":"2021","unstructured":"Schmidt J, Smith AR, Magnin M, Racle J, Devlin JR, Bobisse S, et al. Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting. Cell Rep Med. 2021;2(2):100194.","journal-title":"Cell Rep Med"},{"key":"9812_CR104","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab160","author":"G Li","year":"2021","unstructured":"Li G, Iyer B, Prasath VBS, Ni Y, Salomonis N. DeepImmuno: deep learning-empowered prediction and generation of immunogenic peptides for T cell immunity. Brief Bioinform. 2021;22(6):bbab160. https:\/\/doi.org\/10.1093\/bib\/bbab160.","journal-title":"Brief Bioinform"},{"issue":"1","key":"9812_CR105","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13073-019-0679-x","volume":"11","author":"C Zhou","year":"2019","unstructured":"Zhou C, Wei Z, Zhang Z, Zhang B, Zhu C, Chen K, et al. pTuneos: prioritizing tumor neoantigens from next-generation sequencing data. Genome Med. 2019;11(1):67.","journal-title":"Genome Med"},{"issue":"7873","key":"9812_CR106","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41586-021-03828-1","volume":"596","author":"K Tunyasuvunakool","year":"2021","unstructured":"Tunyasuvunakool K, Adler J, Wu Z, Green T, Zielinski M, \u017d\u00eddek A, et al. Highly accurate protein structure prediction for the human proteome. Nature. 2021;596(7873):590\u20136.","journal-title":"Nature"},{"issue":"1","key":"9812_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81749-9","volume":"11","author":"Z Yang","year":"2021","unstructured":"Yang Z, Bogdan P, Nazarian S. An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study. Sci Rep. 2021;11(1):3238.","journal-title":"Sci Rep"},{"issue":"7873","key":"9812_CR108","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583\u20139.","journal-title":"Nature"},{"issue":"8","key":"9812_CR109","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s42256-023-00694-6","volume":"5","author":"BA Albert","year":"2023","unstructured":"Albert BA, Yang Y, Shao XM, Singh D, Smit KN, Anagnostou V, et al. Deep neural networks predict class I major histocompatibility complex epitope presentation and transfer learn neoepitope immunogenicity. Nat Mach Intell. 2023;5(8):861\u201372.","journal-title":"Nat Mach Intell"},{"key":"9812_CR110","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxaf034","author":"E Karp-Tatham","year":"2025","unstructured":"Karp-Tatham E, Knight JC, Bolze A. Human genetics of responses to vaccines. Clin Exp Immunol. 2025;219(1):uxaf034. https:\/\/doi.org\/10.1093\/cei\/uxaf034.","journal-title":"Clin Exp Immunol"},{"issue":"14","key":"9812_CR111","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1016\/j.vaccine.2023.02.009","volume":"41","author":"MZ Dudley","year":"2023","unstructured":"Dudley MZ, Gerber JE, Budigan Ni H, Blunt M, Holroyd TA, Carleton BC, et al. Vaccinomics: a scoping review. Vaccine. 2023;41(14):2357\u201367.","journal-title":"Vaccine"},{"issue":"6","key":"9812_CR112","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1128\/CVI.00492-07","volume":"15","author":"CC Wilson","year":"2008","unstructured":"Wilson CC, Newman MJ, Livingston BD, MaWhinney S, Forster JE, Scott J, et al. Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy. Clin Vaccine Immunol. 2008;15(6):986\u201394.","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"9812_CR113","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41541-024-00876-2","volume":"9","author":"B Julg","year":"2024","unstructured":"Julg B, Stephenson KE, Tomaka F, Walsh SR, Sabrina Tan C, Lavreys L, et al. Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy. npj Vaccines. 2024;9(1):89.","journal-title":"npj Vaccines"},{"issue":"10","key":"9812_CR114","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/s41577-024-01030-8","volume":"24","author":"TR Mosmann","year":"2024","unstructured":"Mosmann TR, McMichael AJ, LeVert A, McCauley JW, Almond JW. Opportunities and challenges for T cell-based influenza vaccines. Nat Rev Immunol. 2024;24(10):736\u201352.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"9812_CR115","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.4110\/in.2024.24.e19","volume":"24","author":"SH Kim","year":"2024","unstructured":"Kim SH, Espa\u00f1o E, Padasas BT, Son JH, Oh J, Webby RJ, et al. Influenza Virus-Derived CD8 T Cell Epitopes: Implications for the Development of Universal Influenza Vaccines. Immune Netw. 2024;24(3):e19.","journal-title":"Immune Netw"},{"issue":"30","key":"9812_CR116","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1016\/j.vaccine.2023.05.027","volume":"41","author":"JJ Feddema","year":"2023","unstructured":"Feddema JJ, Fernald KDS, Schikan HGCP, van de Burgwal LHM. Upscaling vaccine manufacturing capacity - key bottlenecks and lessons learned. Vaccine. 2023;41(30):4359\u201368.","journal-title":"Vaccine"},{"issue":"3","key":"9812_CR117","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41587-023-01774-z","volume":"42","author":"A vander Straeten","year":"2024","unstructured":"vander Straeten A, Sarmadi M, Daristotle JL, Kanelli M, Tostanoski LH, Collins J, et al. A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines. Nat Biotechnol. 2024;42(3):510\u20137.","journal-title":"Nat Biotechnol"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09812-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-026-09812-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09812-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T07:02:19Z","timestamp":1785567739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-026-09812-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":117,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9812"],"URL":"https:\/\/doi.org\/10.1007\/s12026-026-09812-z","relation":{},"ISSN":["1559-0755"],"issn-type":[{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"not applicable.","order":1,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During manuscript preparation, AI (GPT-5.5) was used to assist with language editing, paraphrasing, grammar correction, and improvement of clarity and readability. The scientific content, interpretation of findings, and primary manuscript draft were developed by the authors. All AI-assisted outputs were critically reviewed, verified, and revised by the authors, who take full responsibility for the accuracy, integrity, and originality of the manuscript.","order":2,"name":"Ethics","label":"AI use declaration","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"not applicable.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"not applicable.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"77"}}